Oncotarget

Search Oncotarget

Clear all
2,090 results found — showing 141–160

Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study Research Paper

Henri Montaudié, Julien Viotti, Patrick Combemale, Caroline Dutriaux, Nicolas Dupin, Caroline Robert, Laurent Mortier, Régis Kaphan, Anne-Bénédicte Duval-Modeste, Stéphane Dalle, Julie De Quatrebarbes, Andrea Stefan, Florence Brunet-Possenti, Maria Kogay, Alexandra Picard-Gauci, Gilles Poissonnet, Frédéric Peyrade
Published Jan 28, 2020 · Vol. 11, No. 4 · pp. 378-385
Keywords: cutaneous squamous cell carcinoma, cetuximab, epidermal growth factor receptor

A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib Research Paper

Wayne D. Blosser, Jack A. Dempsey, Ann M. McNulty, Xi Rao, Philip J. Ebert, Caitlin D. Lowery, Philip W. Iversen, Yue Wang Webster, Gregory P. Donoho, Xueqian Gong, Farhana F. Merzoug, Sean Buchanan, Karsten Boehnke, Chunping Yu, Xin Tian You, Richard P. Beckmann, Wenjuan Wu, Samuel C. McNeely, Aimee Bence Lin, Ricardo Martinez
Published Jan 21, 2020 · Vol. 11, No. 3 · pp. 216-236
Keywords: CHK1, prexasertib, replication stress, replication fork, innate immunity

Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer Research Paper

Yoshimasa Miyagawa, Ayako Yanai, Takehiro Yanagawa, Junichi Inatome, Chiyomi Egawa, Arisa Nishimukai, Kaori Takamoto, Takashi Morimoto, Yuichiro Kikawa, Hirofumi Suwa, Tomoe Taji, Ai Yamaguchi, Yuki Okada, Atsushi Sata, Reiko Fukui, Ayako Bun, Hiromi Ozawa, Tomoko Higuchi, Yukie Fujimoto, Michiko Imamura, Yasuo Miyoshi
Published Jan 7, 2020 · Vol. 11, No. 1 · pp. 86-98
Keywords: breast cancer, bevacizumab, neutrophil-to-lymphocyte ratio, c-reactive protein, predictive marker

Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer Research Paper

Yoshimasa Miyagawa, Ayako Yanai, Takehiro Yanagawa, Junichi Inatome, Chiyomi Egawa, Arisa Nishimukai, Kaori Takamoto, Takashi Morimoto, Yuichiro Kikawa, Hirofumi Suwa, Tomoe Taji, Ai Yamaguchi, Yuki Okada, Atsushi Sata, Reiko Fukui, Ayako Bun, Hiromi Ozawa, Tomoko Higuchi, Yukie Fujimoto, Michiko Imamura, Yasuo Miyoshi
Published Dec 31, 2019
Keywords: Breast cancer, bevacizumab, neutrophil-to-lymphocyte ratio, c-reactive protein, predictive marker

Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer Research Paper

Yoshimasa Miyagawa, Ayako Yanai, Takehiro Yanagawa, Junichi Inatome, Chiyomi Egawa, Arisa Nishimukai, Kaori Takamoto, Takashi Morimoto, Yuichiro Kikawa, Hirofumi Suwa, Tomoe Taji, Ai Yamaguchi, Yuki Okada, Atsushi Sata, Reiko Fukui, Ayako Bun, Hiromi Ozawa, Tomoko Higuchi, Yukie Fujimoto, Michiko Imamura, Yasuo Miyoshi
Published Dec 31, 2019
Keywords: Breast cancer, bevacizumab, neutrophil-to-lymphocyte ratio, c-reactive protein, predictive marker

Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer Research Paper

Yoshimasa Miyagawa, Ayako Yanai, Takehiro Yanagawa, Junichi Inatome, Chiyomi Egawa, Arisa Nishimukai, Kaori Takamoto, Takashi Morimoto, Yuichiro Kikawa, Hirofumi Suwa, Tomoe Taji, Ai Yamaguchi, Yuki Okada, Atsushi Sata, Reiko Fukui, Ayako Bun, Hiromi Ozawa, Tomoko Higuchi, Yukie Fujimoto, Michiko Imamura, Yasuo Miyoshi
Published Dec 31, 2019
Keywords: Breast cancer, bevacizumab, neutrophil-to-lymphocyte ratio, c-reactive protein, predictive marker

Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses Research Paper

Weng In Leong, Rachel Y. Ames, Jessica M. Haverkamp, Laura Torres, Janine Kline, Ashil Bans, Lauren Rocha, Marilena Gallotta, Cristiana Guiducci, Robert L. Coffman, Mary J. Janatpour
Published Dec 31, 2019 · Vol. 10, No. 68 · pp. 7220-7237
Keywords: TLR9, SD-101, cyclophosphamide, immune therapy, innate immunity

Head and neck squamous cancer progression is marked by CLIC4 attenuation in tumor epithelium and reciprocal stromal upregulation of miR-142-3p, a novel post-transcriptional regulator of CLIC4 Research Paper

Brandi L. Carofino, Kayla M. Dinshaw, Pui Yan Ho, Christophe Cataisson, Aleksandra M. Michalowski, Andrew Ryscavage, Addie Alkhas, Nathan W. Wong, Vishal Koparde, Stuart H. Yuspa
Published Dec 31, 2019 · Vol. 10, No. 68 · pp. 7251-7275
Keywords: in situ hybridization, single-cell RNA-sequencing, stroma, miRNA, immune infiltration

A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib Research Paper

Wayne D. Blosser, Jack A. Dempsey, Ann M. Mc Nulty, Xi Rao, Philip J. Ebert, Caitlin D. Lowery, Philip W. Iversen, Yue Wang Webster, Gregory P. Donoho, Xueqian Gong, Farhana F. Merzoug, Sean Buchanan, Karsten Boehnke, Chunping Yu, Xin Tian You, Richard P. Beckmann, Wenjuan Wu, Samuel C. McNeely, Aimee Bence Lin, Ricardo Martinez
Published Dec 16, 2019
Keywords: CHK1, prexasertib, replication stress, replication fork, innate immunity

A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib Research Paper

Wayne D. Blosser, Jack A. Dempsey, Ann M. Mc Nulty, Xi Rao, Philip J. Ebert, Caitlin D. Lowery, Philip W. Iversen, Yue Wang Webster, Gregory P. Donoho, Xueqian Gong, Farhana F. Merzoug, Sean Buchanan, Karsten Boehnke, Chunping Yu, Xin Tian You, Richard P. Beckmann, Wenjuan Wu, Samuel C. McNeely, Aimee Bence Lin, Ricardo Martinez
Published Dec 16, 2019
Keywords: CHK1, prexasertib, replication stress, replication fork, innate immunity

A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib Research Paper

Wayne D. Blosser, Jack A. Dempsey, Ann M. Mc Nulty, Xi Rao, Philip J. Ebert, Caitlin D. Lowery, Philip W. Iversen, Yue Wang Webster, Gregory P. Donoho, Xueqian Gong, Farhana F. Merzoug, Sean Buchanan, Karsten Boehnke, Chunping Yu, Xin Tian You, Richard P. Beckmann, Wenjuan Wu, Samuel C. McNeely, Aimee Bence Lin, Ricardo Martinez
Published Dec 16, 2019
Keywords: CHK1, prexasertib, replication stress, replication fork, innate immunity

A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib Research Paper

Wayne D. Blosser, Jack A. Dempsey, Ann M. Mc Nulty, Xi Rao, Philip J. Ebert, Caitlin D. Lowery, Philip W. Iversen, Yue Wang Webster, Gregory P. Donoho, Xueqian Gong, Farhana F. Merzoug, Sean Buchanan, Karsten Boehnke, Chunping Yu, Xin Tian You, Richard P. Beckmann, Wenjuan Wu, Samuel C. McNeely, Aimee Bence Lin, Ricardo Martinez
Published Dec 16, 2019
Keywords: CHK1, prexasertib, replication stress, replication fork, innate immunity
By using our site you are giving us permission to use cookies. This website collects cookies to deliver a better user experience, and to analyze our website traffic and performance. Personal data is not collected.